Stock Ratings / Health Care / SKYE / options

SCNX (42) ALZN (47) ACXP (39) LGVN (32) ⌘ Pro Terminal →

Skye Bioscience Inc. (SKYE) Options Positioning, Max Pain & Unusual Sweeps

Q: What is SKYE's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for SKYE.

$1.31 -13.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Skye Bioscience Inc. (SKYE) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $5.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SKYE)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (SKYE)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for SKYE.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SKYE)

✓Walkthrough of SKYE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SKYE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -81.37%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.37H $1.42L $1.28C $1.31VOL 40.6K

RES: $6.66SUP: $0.74SMA50: $1.73SMA200: $4.86

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SKYE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SKYE Butterfly Map → + Track SKYE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SKYE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SKYE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SKYE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SKYE)

Health Care Rank #801 of 1016 ⚔️ SCNX vs SKYE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SKYE vs. SCNX, ALZN, ACXP, LGVN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Skye Bioscience Inc. (SKYE) ranks #801 by composite RQD confidence (36/100, grade D-) and #931 by equity capitalization ($5.8M). Within this direct 5-issuer industry benchmark cohort, SKYE leads on earnings valuation at N/A trailing P/E, while SKYE leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ALZN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with SKYE at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SKYE ACTIVE Skye Bioscience Inc.	D-	36/100	—	—	-35.0%	-13.82%	$5.8M	Benchmark Subject
SCNX Scienture Holdings Inc.	D-	42/100	—	76.8%	-35.0%	+2.65%	$5.7M	/scnx-vs-skye →
ALZN Alzamend Neuro Inc.	D	47/100	—	—	-35.0%	+2.52%	$5.9M	/alzn-vs-skye →
ACXP Acurx Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	0.00%	$5.9M	/acxp-vs-skye →
LGVN Longeveron Inc. (Class A)	E	32/100	—	67.0%	-35.0%	-1.68%	$5.6M	/lgvn-vs-skye →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001516551

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Skye Bioscience Inc. (SKYE) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$55.9M, operating cash flow of -$43.1M, and free cash flow of -$43.1M (-60.5% YoY). On the balance sheet, SKYE closed FY2025 with $28.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$55.9M	-$43.1M	-$43.1M	$28.3M	—
FY2024 (FY)	2024-12-31	$0	-$26.6M	-$25.2M	-$26.8M	$72.8M	—
FY2023 (FY)	2023-12-31	$0	-$37.6M	-$14.0M	-$14.0M	—	—

3. SKYE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SKYE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Skye Bioscience Inc. (NASDAQ: SKYE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.31 (-13.82% 1D, market cap $5.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SKYE ranks #801 in composite RQD confidence.

How does SKYE compare to SCNX and ALZN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SKYE carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SCNX (Scienture Holdings Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M) and ALZN (Alzamend Neuro Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $5.9M). Among the 5-stock peer group, SKYE leads on earnings multiple (N/A) while SKYE leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SKYE?

Per SKYE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001516551), Skye Bioscience Inc. generated $0 in revenue, -$55.9M in net income, and -$43.1M in free cash flow against $28.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SKYE trading relative to its 50-day, 200-day, and 52-week technical levels?

SKYE last traded at $1.31 (-13.82% on volume of 34,771 shares), positioning the stock -24.28% below its 50-day simple moving average ($1.73) and -73.05% below its 200-day simple moving average ($4.86). Across its 52-week range of $1.25 to $12.80, SKYE sits at the 0.5% percentile with a 14-day RSI of 31.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.15 to $1.47).

SKYE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is SKYE's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for SKYE.

Direct Sub-Reports: SKYE RQD Cockpit SKYE 12M Forecast SKYE Earnings & Move SKYE Dividends & DRIP SKYE Insiders & 13F SKYE Whale Options SKYE Profit Sankey SKYE News & Why